Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)].
Harper
Richard P
RP
Oral and Maxillofacial Surgery, University of Texas Southwestern Medical Center, Waco, and Corsicana 75110, USA. drharp@sbcglobal.net
Fung
Eugene
E
D000368:Aged; D019386:Alendronate / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D002985:Clinical Protocols; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008336:Mandibular Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy*; D019379:Teriparatide / Q000008:administration & dosage*; D014081:Tooth Extraction / Q000009:adverse effects
D050071:Bone Density Conservation Agents; D019379:Teriparatide; D019386:Alendronate